Kenneth Harrison
Direktor/Vorstandsmitglied bei Claris Biotherapeutics, Inc.
Profil
Kenneth Harrison is currently a Director at Glycomine, Inc., Aristea Therapeutics, Inc., Claris Biotherapeutics, Inc., Nuvig Therapeutics, Inc., a Partner at Novo Ventures 1 A, and a Principal at Novo Ventures (US), Inc. He previously held positions as an Independent Director at Reneo Pharmaceuticals, Inc., an Independent Non-Executive Director at Edgewise Therapeutics, Inc., a Senior Manager-Market Planning at Genentech, Inc., a Partner at Mission Bay Capital Management, Inc., and a Manager-Entrepreneurship Program at California Institute For Quantitative Biosciences.
Harrison received his undergraduate degree from Texas Tech University and his doctorate from Yale School of Medicine.
Aktive Positionen von Kenneth Harrison
| Unternehmen | Position | Beginn |
|---|---|---|
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Private Equity Investor | 01.11.2015 |
Claris Biotherapeutics, Inc.
 Claris Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Claris Biotherapeutics, Inc. engages in the manufacturing of drugs. The company was founded in 2018 and is headquartered in Jersey City, NJ. | Direktor/Vorstandsmitglied | - |
Glycomine, Inc.
 Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Direktor/Vorstandsmitglied | - |
Aristea Therapeutics, Inc.
 Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA. | Direktor/Vorstandsmitglied | - |
Nuvig Therapeutics, Inc.
 Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Direktor/Vorstandsmitglied | - |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Private Equity Investor | 01.11.2015 |
Ehemalige bekannte Positionen von Kenneth Harrison
| Unternehmen | Position | Ende |
|---|---|---|
| EDGEWISE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 21.06.2023 |
| RENEO PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 20.01.2022 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01.11.2015 |
| ░░░░░░░ ░░░ ░░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░░░░░ ░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Kenneth Harrison
| Texas Tech University | Undergraduate Degree |
| Yale School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| RENEO PHARMACEUTICALS, INC. | Health Technology |
| EDGEWISE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Finance |
Mission Bay Capital Management, Inc.
 Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | Finance |
California Institute For Quantitative Biosciences
 California Institute For Quantitative Biosciences Investment ManagersFinance Part of University of California, California Institute For Quantitative Biosciences is a biotech company that offers internships to UC students through its state-funded Qwest internship program. The company is based in San Francisco, CA and was founded in 2000. The program places students with Bakar Labs tenant companies for work experience, and four of its first cohort have already received full-time job offers from their hosts. The company conducts proof-of-concept experiments in a mouse model of ALS and offers mentoring programs to early-stage companies. | Finance |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Finance |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Health Technology |
Aristea Therapeutics, Inc.
Aristea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aristea Therapeutics, Inc. operates as a clinical-stage drug development company. It develops novel therapies to treat serious inflammatory diseases. The company was founded by James Morrison MacKay in 2018 and is headquartered in Poway, CA. | Health Technology |
Claris Biotherapeutics, Inc.
Claris Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Claris Biotherapeutics, Inc. engages in the manufacturing of drugs. The company was founded in 2018 and is headquartered in Jersey City, NJ. | Health Technology |
Nuvig Therapeutics, Inc.
Nuvig Therapeutics, Inc. BiotechnologyHealth Technology Nuvig Therapeutics, Inc. is a company that is focused on developing innovative therapies for patients with chronic autoimmune diseases. The company is based in Redwood City, CA. The company's goal is to induce natural mechanisms that restore immune homeostasis and rebalance immune function following inflammation. Nuvig Therapeutics was founded by Greg Coffey, Jeffrey V. Ravetch, Sheldon L. Koenig, Pamela B. Conley, Joanne M. Quan. Julie Anne Smith has been the CEO of the company since 2023. | Health Technology |
